| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000036893 |
| Receipt No. | R000042044 |
| Scientific Title | Effects of a Test Food for Cognitive Function (1) |
| Date of disclosure of the study information | 2019/06/20 |
| Last modified on | 2020/08/03 (Ver. 7) |
| Basic information | ||
| Public title | Effects of a Test Food for Cognitive Function (1) | |
| Acronym | Effects of a Test Food for Cognitive Function (1) | |
| Scientific Title | Effects of a Test Food for Cognitive Function (1) | |
| Scientific Title:Acronym | Effects of a Test Food for Cognitive Function (1) | |
| Region |
|
|
| Condition | |||
| Condition | N/A(healthy adults) | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | This study aims to examine effects of a test food for cognitive function. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Japanese version of the CNS Vital Signs (Cognitrax) |
| Key secondary outcomes | Doctor's qustions, blood glucose |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Single oral ingestion of the test food (once) | |
| Interventions/Control_2 | Single oral ingestion of the placebo food (once) | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Japanese individuals aged 20-39 years.
2)Individuals who are healthy and are not suffered from a chronic malady. 3)Individuals whose written informed consent has been obtained. 4)Individulals who can visit an inspection facility and be inspected in designated days. 5)Individuals judged appropriate for the study by the principal. 6)Individuals who can draw blood from a fingertip. |
|||
| Key exclusion criteria | 1)Individuals using medical products.
2)Individuals with dementia. 3)Individuals with high blood glucose (fasting blood glucose over 100 mg/dL). 4)Individuals who used a drug for treatment of disease in the past 1 month. 5)Individuals who have a history of serious hepatopathy, kidney damage, heart disease, hematological and blood disease. 6)Individuals who contract or have a history of serious gastrointestinal disease. 7)Individuals with serious anemia. 8)Individuals who contract or have a history of food allergy. (milk, gelatin) 9)Females who are or are possibly pregnant, or are lactating. 10)Individuals who have an addiction to alcohol or a mental illness. 11)Individuals who are a smoker. 12)Individuals whose life style will change during the test period. 13)Individuals with probable seasonal allergy, such as pollinosis, during the test period.(Betulaceae: alder, oba alnus firma, shirakaba, Taxodiaceae: cryptomeria, hinoki cypress, Asteraceae: ragweed, Artemisia vulgaris indica, Gramineae:Dactylis glomerata, Phleum pratense) 14)Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements in the past 3 months or will ingest those foods during the test period. 15)Individuals who had a habit to ingest foods claiming to improve cognitive function, foods for specified health uses, health foods, or supplements in the past 3 months or will ingest those foods during the test period. 16)Individuals who have a habit to use drug claiming to improve cognitive function in the past 3 months. 17)Individuals who conducted hormone replacement therapy in the past 6 months or have a history of conducting hormone replacement therapy. 18)Individuals who were hospitalized and received treatment in the past 6 months, or will be hospitalized during the test period. 19)Individuals who participated in other clinical studies in the past 1 months. 20)Individuals judged inappropriate for the study by the principal. |
|||
| Target sample size | 12 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Morinaga & Co.,Ltd | ||||||
| Division name | Health Science and Research Center, R&D institute | ||||||
| Zip code | 230-8504 | ||||||
| Address | 2-1-1, Shimodueyoshi, Tsurumi-ku, Yokohama | ||||||
| TEL | 045-571-6140 | ||||||
| m-morita-je@morinaga.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | MORINAGA & CO., LTD. | ||||||
| Division name | Health Science and Research Center, R&D institute | ||||||
| Zip code | 230-8504 | ||||||
| Address | 2-1-1, Shimodueyoshi, Tsurumi-ku, Yokohama | ||||||
| TEL | 045-571-6140 | ||||||
| Homepage URL | |||||||
| s-mori-ab@morinaga.co.jp | |||||||
| Sponsor | |
| Institute | MORINAGA & CO., LTD. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | MORINAGA & CO., LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Japan Aesthetic Dermatology Symposium |
| Address | 15-1-604,Himonya 5-Chome,Meguro-ku,Tokyo,Japan |
| Tel | 03-3794-1235 |
| info@jp-ads.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 14 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042044 |